Reata Pharmaceuticals (RETA) Upgraded to Hold at BidaskClub

BidaskClub upgraded shares of Reata Pharmaceuticals (NASDAQ:RETA) from a sell rating to a hold rating in a report issued on Saturday morning.

A number of other research firms have also recently issued reports on RETA. ValuEngine raised Reata Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 26th. Zacks Investment Research raised Reata Pharmaceuticals from a strong sell rating to a hold rating in a research report on Tuesday, October 24th. Cowen reaffirmed a buy rating on shares of Reata Pharmaceuticals in a research report on Tuesday, November 14th. Robert W. Baird reaffirmed a buy rating and issued a $47.00 price objective on shares of Reata Pharmaceuticals in a research report on Tuesday, October 24th. Finally, Jefferies Group reaffirmed a buy rating and issued a $44.00 price objective on shares of Reata Pharmaceuticals in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $54.71.

Shares of Reata Pharmaceuticals (NASDAQ:RETA) traded up $0.18 during midday trading on Friday, reaching $29.79. The company had a trading volume of 105,856 shares, compared to its average volume of 135,187. Reata Pharmaceuticals has a 1 year low of $19.48 and a 1 year high of $40.88. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of -0.15. The firm has a market capitalization of $777.91, a PE ratio of -19.47 and a beta of -3.11.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.11). The company had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. The firm’s revenue was up .0% compared to the same quarter last year. sell-side analysts forecast that Reata Pharmaceuticals will post -1.91 earnings per share for the current fiscal year.

In other news, Director Cpmg Inc bought 200,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were bought at an average price of $24.79 per share, for a total transaction of $4,958,000.00. Following the completion of the purchase, the director now owns 113 shares in the company, valued at $2,801.27. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James Edward Bass bought 3,888 shares of the stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average price of $24.02 per share, for a total transaction of $93,389.76. Following the purchase, the director now owns 52,089 shares of the company’s stock, valued at approximately $1,251,177.78. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 413,813 shares of company stock worth $10,453,354. 44.00% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in RETA. Sphera Funds Management LTD. bought a new position in shares of Reata Pharmaceuticals during the third quarter worth approximately $6,376,000. Emerald Mutual Fund Advisers Trust increased its stake in shares of Reata Pharmaceuticals by 60.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock worth $14,712,000 after purchasing an additional 179,124 shares during the period. FMR LLC increased its stake in shares of Reata Pharmaceuticals by 74.4% during the second quarter. FMR LLC now owns 414,491 shares of the company’s stock worth $13,114,000 after purchasing an additional 176,885 shares during the period. Emerald Advisers Inc. PA increased its stake in shares of Reata Pharmaceuticals by 40.1% during the third quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock worth $17,709,000 after purchasing an additional 162,990 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Reata Pharmaceuticals by 109.6% during the second quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock worth $9,350,000 after purchasing an additional 154,515 shares during the period. Institutional investors own 29.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/21/reata-pharmaceuticals-reta-upgraded-to-hold-at-bidaskclub.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply